Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-25Clinical Trial Update: Serum Potassium Prediction Using Machine Learning and Single-lead ECG
A Brigham and Women's Hospital clinical trial evaluating potassium prediction from machine learning and a single-lead ECG has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2026-03-18Clinical Trial Update: EXACOS EG Population
AstraZeneca's EXACOS EG Population trial in chronic obstructive pulmonary disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-27Clinical Trial Update: Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease [NA]
A probiotic clinical trial investigating Type 2 diabetes mellitus and chronic obstructive pulmonary disease was terminated.
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Eecentric Exercise on Cardiopulmonary Fitness and Quality of Life With Chronic Obstructive Pulmonary Disease [NA]
The clinical trial investigating eccentric exercise to improve cardiopulmonary fitness and quality of life in chronic obstructive pulmonary …
-
CLINICAL_TRIALS withdrawal · 2026-01-20Clinical Trial Update: Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation
The clinical trial evaluating hyperpolarized xenon imaging in COPD patients undergoing targeted lung denervation has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-12-17Clinical Trial Update: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) [Phase 3]
A Phase 3 trial evaluating two doses of CHF6001 DPI (tanimilast) as add-on to maintenance triple therapy in chronic obstructive pulmonary di…
-
CLINICAL_TRIALS withdrawal · 2025-10-24Clinical Trial Update: Heat Waves and the Elderly With COPD [NA]
A clinical trial sponsored by the University of Texas Southwestern Medical Center evaluating heat waves effects in elderly patients with chr…
-
CLINICAL_TRIALS withdrawal · 2025-09-26Clinical Trial Update: Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease [NA]
A clinical trial investigating unrefined salmon oil as a dietary supplement in patients with chronic obstructive pulmonary disease has been …
-
CLINICAL_TRIALS withdrawal · 2025-08-27Clinical Trial Update: Accessing Mobility Using Wearable Sensors [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating mobility with wearable sensors in patients with COPD and related cardiopulmonary conditions has been w…
-
CLINICAL_TRIALS withdrawal · 2025-04-01Clinical Trial Update: Extracorporeal CO2 Removal for Acute Decompensation of COPD [NA]
The clinical trial evaluating extracorporeal CO2 removal for acute decompensation of chronic obstructive pulmonary disease has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2025-03-20Clinical Trial Update: A Mobile Integrated Health Intervention to Manage Congestive Health Failure and Chronic Obstructive Pulmonary Disease
A clinical trial evaluating a mobile integrated health intervention for congestive heart failure and chronic obstructive pulmonary disease h…
-
EMA withdrawal · 2025-03-18EMA Withdrawn: Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) (formoterol fumarate dihydrate;glycopyrronium;beclometasone dipropionate) — Chiesi Farmaceutici S.p.A.
EMA has withdrawn the COPD inhaler Riarify, a fixed-dose triple therapy containing formoterol fumarate dihydrate, glycopyrronium, and beclom…
-
CLINICAL_TRIALS withdrawal · 2025-01-20Clinical Trial Update: Promoting Activity After COPD Exacerbations, Aim 2 [NA]
The trial Promoting Activity After COPD Exacerbations, Aim 2 sponsored by the University of Illinois at Chicago has been terminated (TERMINA…
-
CLINICAL_TRIALS withdrawal · 2024-12-11Clinical Trial Update: Remote Monitoring of Respiratory Health [NA]
Stanford University’s remote monitoring of respiratory health trial has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures [NA]
A university-sponsored clinical trial investigating maximizing benefit of lung cancer screening by evaluating incidental findings in cardiov…
-
CLINICAL_TRIALS withdrawal · 2024-11-27Clinical Trial Update: Quantitative Lung Cancer Screening
The ClinicalTrials.gov entry for Quantitative Lung Cancer Screening has been withdrawn. The study was associated with chronic obstructive pu…
-
CLINICAL_TRIALS withdrawal · 2024-05-17Clinical Trial Update: Oral Iloprost for the Prevention of Lung Cancer In Former Smokers [Phase 2]
Phase 2 trial of oral iloprost for prevention of lung cancer in former smokers has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: The UCAP 2 Pilot Study [NA]
The UCAP 2 Pilot Study has been withdrawn from clinical trial.
-
CLINICAL_TRIALS withdrawal · 2024-02-01Clinical Trial Update: IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US [Phase 4]
Phase 4 clinical trial IKANOS evaluating Breztri maintenance versus non-triple inhaled therapy after COPD hospitalization has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2023-05-06Clinical Trial Update: A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema [Phase 4]
Phase 4 trial of RYMPHYSIA for A1PI deficiency in adults with COPD-emphysema has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-02-23Clinical Trial Update: TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial - Study Protocol [Phase 4]
A Phase 4 clinical trial (TOBacco STOP in Chronic Obstructive Pulmonary Disease-Trial) has been withdrawn.
-
EMA withdrawal · 2022-11-24EMA Lapsed: Temybric Ellipta (fluticasone furoate;umeclidinium bromide;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited
The EMA lists Temybric Ellipta as lapsed in the European market.
-
CLINICAL_TRIALS withdrawal · 2022-10-27Clinical Trial Update: Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD [Phase 4]
Phase 4 trial investigating cardiac effects of Spiolto/Respimat in patients with COPD was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-09-02Clinical Trial Update: Sequential Endoscopic Lung Volume Reduction [Phase 3]
Phase 3 trial of sequential endoscopic lung volume reduction in emphysema/COPD has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-08-30Clinical Trial Update: Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
A Phase 4 trial evaluating appropriate inhaler use in COPD has been withdrawn.